Immix Biopharma Inc.

10/02/2025 | Press release | Distributed by Public on 10/02/2025 14:35

Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.